Clinical Trials Search Results

1.

Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077

2.

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658

3.

Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 365 days to 30 years
Trial IDs: ANBL1531, NCI-2016-01734, NCT03126916

4.

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849

5.

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: IRB00005056, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398

6.

Lenalidomide as Maintenance Therapy after Combination Chemotherapy with or without Rituximab and Stem Cell Transplant in Treating Patients with Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 446-08, NCI-2009-01436, RV-LYM-PI-0328, NCT01035463

7.

Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136

8.

Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387

9.

Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, NCT02053545

10.

CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800

11.

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 45 and under
Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512

12.

Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant

Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403

13.

Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype

Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145

14.

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients with High-Risk Multiple Myeloma

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 16464, NCI-2017-00512, NCT03100877

15.

Selinexor, High-Dose Melphalan, and Dexamethasone before Stem Cell Transplant in Treating Patients with Multiple Myeloma

Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18630, NCI-2017-01190, NCT02780609

16.

Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome

Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, HS# 0511M77206, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565

17.

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895

18.

High-Dose Chemotherapy, Bevacizumab, and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors

Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936

19.

Disease-Specific High-Dose Conditioning Regimens in Treating Patients Undergoing T-cell Depleted Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies or Other Lethal Hematologic Disorders

Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 69
Trial IDs: 10-050, NCI-2010-01240, NCT01119066

20.

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and under
Trial IDs: 2260.00, NCI-2010-00403, FHCRC-2260.00, 6733, FHCRC-IR-6733, NCT00716066

21.

Intra-arterial Melphalan in Treating Younger Patients with Localized Intraocular Retinoblastoma

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: J1071, NCI-2011-00584, NA_000040637, NCT01293539

22.

Ipilimumab and Isolated Limb Infusion With Melphalan and Dactinomycin in Treating Patients With Advanced Melanoma of The Extremity That Cannot Be Removed by Surgery

Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-101, NCI-2012-00223, 10-101A(4), NCT01323517

23.

Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors

Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NCT01804634

24.

Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies

Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611

25.

Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

Status: Active
Phase: Phase II
Type: Treatment
Age: Under 19
Trial IDs: NB2012, NCI-2013-00034, NCT01857934

Clinical Trials Search Results

Results 1-25 of 53 for your search: